Resultado de búsqueda
Hace 18 horas · CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition ...
Hace 18 horas · Exceeded enrollment target due to patient demand; trial size increased to 121 patients Bempikibart topline results remain on track to be released ...
Hace 6 horas · Argot Partners Sarah Sutton / Kevin Murphy [email protected] (212) 600-1902. SOURCE CalciMedica, Inc.
Hace 6 horas · KOURAGE is a randomized, double-blind, placebo-controlled study that will evaluate 150 patients with Stage 2 and 3 AKI who have AHRF and are receiving oxygen by non-invasive mechanical ventilation, high flow nasal cannula or intermittent mandatory ventilation (IMV). AKI denotes a sudden reduction in kidney function, the organ's ability to clean ...
Hace 6 horas · LA JOLLA, Calif., July 9, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium ...
Hace 18 horas · Q32 Bio Inc. ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that it has completed enrollment in the ...
Hace 18 horas · Q32 Bio announced the completion of patient enrollment for its SIGNAL-AD Phase 2 clinical trial of bempikibart for atopic dermatitis (AD). The trial surpassed its target, enrolling 121 patients due to high demand.
